Medicare and GLP-1 weight loss drugs have a complicated history. For years, Medicare would only cover GLP-1s if you had type 2 diabetes — not for weight loss alone. That changed on May 6, 2026, when CMS announced the Medicare GLP-1 Bridge: a short-term demonstration program that gives eligible Part D beneficiaries access to certain GLP-1 drugs for $50 per month, starting July 1, 2026.
Here is what you need to know.
Quick Answer
Starting July 1, 2026, eligible Medicare Part D beneficiaries can get Wegovy, Zepbound (KwikPen), or Foundayo for $50/month through the Medicare GLP-1 Bridge. Your doctor must submit a prior authorization confirming you meet clinical criteria. You do not need to register or opt in. The program runs through December 31, 2027.
This is not permanent coverage — it is a demonstration program. But it is the most significant expansion of Medicare GLP-1 access in years.
The Background: Why This Matters
For a long time, Medicare had a rule: it would not cover weight loss drugs. This dated back to a 2003 law that excluded "weight loss agents" from Medicare Part D coverage.
GLP-1s changed the conversation. Drugs like Wegovy and Zepbound are not just for weight loss — they reduce the risk of heart attack and stroke in people with cardiovascular disease. That medical benefit made it harder for Medicare to justify keeping them excluded.
CMS created the bridge program as a temporary solution. It lets Medicare cover GLP-1s for obesity treatment while broader policy decisions are worked out.
What Changed: The May 2026 Announcement
On May 6, 2026, CMS formally announced the Medicare GLP-1 Bridge with specific details:
- $50/month copay for eligible GLP-1 drugs
- Starts July 1, 2026 — runs through December 31, 2027
- Operates outside the Part D benefit — Part D plans do not need to opt in, and the $50 copay does not count toward your out-of-pocket (TrOOP) costs
- Central processor handles prior authorization, claims adjudication, and pharmacy payments
- No beneficiary registration required — your doctor submits the prior auth
CMS Administrator Dr. Mehmet Oz stated: "These treatments are a major medical advancement, but too many seniors are currently unable to access them due to high cost. The Medicare GLP-1 Bridge changes that."
The program was extended through December 2027 because the BALANCE Model — a planned longer-term coverage model — is not launching in 2027. CMS will use the additional time to collect utilization data and share it with Part D sponsors ahead of potential broader implementation.
Which GLP-1 Drugs Are Covered
The Bridge covers three medications when prescribed for weight management:
| Drug | Formulation | Included? |
|---|---|---|
| Foundayo (orforglipron) | All formulations | Yes |
| Wegovy (semaglutide) | Injection and tablets | Yes |
| Zepbound (tirzepatide) | KwikPen only | Yes |
| Zepbound (tirzepatide) | Single-dose vial and single-dose pen | No |
| Ozempic | Injection | No — not FDA-approved for weight management |
| Mounjaro | Injection | No — not FDA-approved for weight management |
| Saxenda | Injection | No — not included in this program |
Why Foundayo? Foundayo (orforglipron) is a daily GLP-1 pill approved by the FDA on April 1, 2026. It was added to the Bridge eligibility list because it offers a no-needle option for patients who cannot or prefer not to use injections. Read our Foundayo guide for dosing, side effects, and availability details.
Why only Zepbound KwikPen? CMS limited Zepbound coverage to the KwikPen formulation. If you currently use the single-dose vial or single-dose pen, talk to your doctor about switching to KwikPen. Our Zepbound pill guide covers the differences between Zepbound formulations.
Important: If you have type 2 diabetes and are prescribed a GLP-1 for blood sugar control, that is already covered under standard Medicare Part D. The Bridge is specifically for people who need GLP-1s for weight management.
Who Qualifies: Clinical Criteria
To be eligible, your doctor must submit a prior authorization confirming you meet all of these requirements:
- You are prescribed the GLP-1 to reduce excess body weight and maintain weight reduction, in combination with lifestyle modification (nutrition and physical activity consistent with the FDA label)
- You are at least 18 years old
- You meet one of these BMI and condition thresholds:
| BMI Threshold | Qualifying Conditions |
|---|---|
| BMI ≥ 35 | None required |
| BMI ≥ 30 | Heart failure with preserved ejection fraction OR uncontrolled hypertension (systolic >140 or diastolic >90 on two antihypertensive meds) OR chronic kidney disease stage 3a+ |
| BMI ≥ 27 | Prediabetes (per ADA guidelines) OR prior myocardial infarction OR prior stroke OR symptomatic peripheral artery disease |
Key exclusions: If you have a diagnosis of type 2 diabetes, obstructive sleep apnea, or noncirrhotic MASH, you are not eligible for the Bridge — because those conditions already qualify for GLP-1 coverage through your regular Part D plan. The Bridge is designed for people who need GLP-1s specifically for weight management.
Eligible plan types: You must be enrolled in a standalone prescription drug plan (PDP) or a Medicare Advantage plan with drug coverage (MA-PD), including HMO, HMOPOS, and local/regional PPO plans. Special Needs Plans (SNPs) and employer/union group waiver plans (EGWPs) are also eligible. Dually-eligible beneficiaries qualify if they meet the prior auth criteria.
Not eligible: Private fee-for-service plans, PACE organizations, fallback plans, and religious fraternal benefit plans — unless you also have a standalone PDP.
How to Get Ready Before July 1
Step 1: Talk to Your Doctor Now
You cannot submit a prior authorization before July 1, but you can prepare. Ask your doctor:
- "Do I meet the clinical criteria for the Medicare GLP-1 Bridge?"
- "Which GLP-1 would be right for me — Wegovy, Zepbound, or Foundayo?"
- "Can you submit the prior authorization form on July 1?"
Your doctor will need to document your BMI, any qualifying conditions, and confirm the prescription is for weight management (not diabetes).
Step 2: Verify Your Plan Type
Check that you are enrolled in an eligible Part D plan. Most Medicare Advantage plans with drug coverage and standalone PDPs qualify. If you are unsure, call the number on your Medicare card and ask: "Is my plan eligible for the Medicare GLP-1 Bridge?"
Step 3: Watch for the Prior Authorization Form
CMS will publish the prior authorization form and submission instructions on the Medicare GLP-1 Bridge webpage in June 2026. CMS encourages electronic submission.
Step 4: Fill Your Prescription After July 1
Once your prior auth is approved, take your prescription to any pharmacy. The central processor handles the claim — you pay $50, and the Bridge covers the rest.
What the $50 Copay Means for Your Costs
The Bridge copay is straightforward: $50 per monthly supply. But there are important details:
- Part D deductible does not apply — you do not need to meet your deductible first
- $50 does not count toward TrOOP — your true out-of-pocket costs for Part D are calculated separately
- No low-income subsidy (LIS) — even if you qualify for Extra Help, you still pay $50
- Copay is per drug, per month — if you switch medications, the copay still applies
For context, without the Bridge, GLP-1 drugs cost $1,000–$1,350/month at list price. Even with Part D coverage for diabetes, copays typically range from $25–$150/month depending on your plan's tier. The Bridge's $50 flat rate is significantly better than paying cash.
See our GLP-1 cost comparison for a full breakdown of GLP-1 pricing across all coverage types.
What the Bridge Does NOT Do
This is where it gets real:
- It is not permanent. The Bridge runs through December 31, 2027. There is no guarantee it becomes standard coverage.
- Not all GLP-1s are included. Ozempic, Mounjaro, and Saxenda are not on the eligible drug list. Only Wegovy, Zepbound (KwikPen), and Foundayo are covered.
- Not all Zepbound formulations are included. Only the KwikPen. If you use vials or single-dose pens, you are not covered.
- Diabetes patients use Part D instead. If you have type 2 diabetes, your GLP-1 is covered through standard Part D — not the Bridge.
- The copay does not help with Part D out-of-pocket limits. The $50 is separate from your Part D spending.
- No LIS for the copay. Low-income subsidy beneficiaries still pay $50.
What Happens When the Bridge Ends
The program runs through December 31, 2027. After that, there are several possibilities:
Possibility 1: Permanent Part D Coverage
Congress could amend the 2003 law that excludes weight loss drugs from Medicare. If that happens, GLP-1s for obesity would become a standard Part D benefit. There is active legislative discussion, but no bill has passed yet.
Possibility 2: The BALANCE Model
CMS was developing the BALANCE Model as a longer-term coverage approach. It is not launching in 2027, which is why the Bridge was extended through December 2027. CMS is collecting data during the Bridge period to inform future policy.
Possibility 3: Program Extension
CMS could extend the Bridge again if permanent coverage is not ready by the end of 2027.
What You Should Do Now
If you benefit from the Bridge program:
- Document your progress. Weight loss, improved blood pressure, better mobility — these outcomes help make the case for permanent coverage.
- Talk to your doctor about transition planning. Know your options before the Bridge ends.
- Stay informed. CMS will share updates on the Medicare GLP-1 Bridge webpage.
Backup Options If Coverage Ends
If the Bridge program ends and you are on a GLP-1, you could lose coverage. Plan ahead:
Manufacturer patient assistance programs. Novo Nordisk and Eli Lilly both offer programs for low-income patients. These can provide medications at reduced cost or free. Income limits apply — usually around 400–500% of the federal poverty level.
Switch to a Medicare Advantage plan with weight loss coverage. During open enrollment, you can switch to a Medicare Advantage plan that includes weight loss medications. Compare plans carefully — coverage varies a lot.
Compounded GLP-1s. Licensed compounding pharmacies can make semaglutide, but note: as of May 2026, semaglutide injection has been removed from the FDA Drug Shortage Database, making compounding legally riskier. Read our compounded GLP-1 safety guide before considering this route.
Talk to your doctor about alternatives. Your doctor may suggest other weight management options that Medicare already covers, such as behavioral counseling (Medicare covers obesity counseling in primary care settings).
How This Connects to Other Coverage Paths
If you are on Medicare and looking for GLP-1 access, you have several paths:
- Bridge program — $50/month for weight management, July 2026–December 2027
- Part D for diabetes — Permanent coverage if you have type 2 diabetes (Ozempic, Mounjaro, and others)
- Manufacturer patient assistance — For low-income patients who cannot afford the $50 copay
- Injection supplies — If prescribed a GLP-1 injection, you will need alcohol prep pads and a sharps container
For seniors weighing the safety considerations of GLP-1 medications, see our GLP-1 for seniors guide. For the full picture on insurance options and appeals, read our GLP-1 insurance coverage guide.
The Bigger Picture
The Medicare GLP-1 Bridge is the biggest expansion of Medicare weight loss drug coverage in over 20 years. A flat $50/month copay, nationwide availability, and no opt-in requirement make it significantly more accessible than the previous patchwork of plan-specific coverage.
But it is a demonstration, not a guarantee. The program collects data that will inform whether GLP-1 weight loss drugs become a permanent Medicare benefit. If you benefit from the Bridge, keep documenting your progress. Weight loss, improved blood pressure, better mobility — these are the outcomes that help make the case for permanent coverage.
Bottom Line
The Medicare GLP-1 Bridge is real, it starts July 1, 2026, and it gives eligible Part D beneficiaries access to Wegovy, Zepbound (KwikPen), or Foundayo for $50/month. Talk to your doctor about whether you meet the clinical criteria, and ask them to submit the prior authorization starting July 1. You do not need to opt in or register. But the program is temporary — plan for what comes after.
For a full breakdown of insurance options for GLP-1s, see our insurance coverage guide. For cost comparisons across all GLP-1 medications, see our GLP-1 cost comparison.
This article is for informational purposes only and does not constitute medical or insurance advice. Medicare coverage varies by plan and changes frequently. Always verify coverage directly with your Medicare plan provider. Program details are based on the CMS press release of May 6, 2026, and the CMS Medicare GLP-1 Bridge FAQ page updated June 3, 2026. Check cms.gov for the most current information.
